Ask AI
ProCE Banner Activity

Personalized Care of Patients With HER2-Positive Advanced BTC and GEA

Clinical Thought

In this commentary, an expert addresses the evolving treatment landscape in the management of patients with HER2-positive BTC and GEA, including the importance of involving patients and their caregivers in the treatment decision-making process.

Released: April 22, 2026

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, nurses, and other HCPs involved in caring for patients with GEA or BTC. Additionally, it aims to empower patients with vital information to actively participate in their treatment decisions, fostering a collaborative approach to their care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Communicate emerging data and ongoing clinical trial opportunities in HER2+ GEA and BTC to educate colleagues and counsel patients, fostering a collaborative environment for decision-making in their treatment journey

  • Identify patients with HER2+ GEA and BTC who could benefit from HER2-targeted therapy

Disclosure

Primary Author

Richard Kim, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Eisai, Elevar, Exelixis, Incyte, Ipsen, Jazz, Roche, Servier, Taiho, Takeda.